

RECEIVED  
CENTRAL FAX CENTER

JAN 21 2004

Law Offices of  
SENNIGER, POWERS, LEAVITT AND ROEDEL  
One Metropolitan Square, 16th Floor  
St. Louis, Missouri 63102  
Telephone (314) 231-5400  
Facsimile (314) 231-4342

## FACSIMILE TRANSMITTAL COVER SHEET

DATE: January 21, 2004 ATTY. DOCKET #: PHA 2012.1 (3167/4Z/US)PTO FACSIMILE NUMBER: (703) 872-9306

PLEASE DELIVER THIS FACSIMILE TO:

ATTN: Examiner Rebecca CookTHIS FACSIMILE IS BEING SENT BY: Kathryn J. DotyNUMBER OF PAGES: 10 INCLUDING COVER SHEETTIME SENT: 2:42 pm OPERATOR'S NAME M. Susan Clements  
(CDT)

## CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that these papers are being transmitted via  
facsimile to the Commissioner for Patents on the date shown  
below.

M. Susan Clements

Typed or printed name of person signing certification

M. Susan Clements

Signature

January 20, 2004

Date

Type of papers transmitted: Supplement to Amendment B and  
Response to Office Action; and PTO/SB/08A Information Disclosure  
Statement (References to be Express Mailed w/Hard Copy)

Applicant's Name: John P. McKearn et al.Reissue Serial No.: 09/857,873Examiner: Rebecca CookFiling Date: October 5, 2001Art Unit: 1614

Application Title: METHOD OF USING A CYCLOOXYGENASE-2 INHIBITOR  
AND ONE OR MORE ANTINEOPLASTIC AGENTS AS A COMBINATION THERAPY IN  
THE TREATMENT OF NEOPLASIA

IF YOU DO NOT RECEIVE ALL PAGES CLEARLY, CALL BACK AS SOON AS  
POSSIBLE. CONFIRMING NUMBER IS (314) 231-5400.

PHA 2012.1 (3167/4Z/US)  
PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED  
CENTRAL FAX CENTER  
JAN 21 2004

Application of J.P. McKearn et al.

Art Unit 1614

Serial No. 09/857,873

Filed October 5, 2001

Confirmation No. 2817

For METHOD OF USING A CYCLOOXYGENASE-2 INHIBITOR AND ONE OR  
MORE ANTINEOPLASTIC AGENTS AS A COMBINATION THERAPY IN THE  
TREATMENT OF NEOPLASIA

Examiner Rebecca Cook

January 21, 2004

**SUPPLEMENT TO AMENDMENT B AND RESPONSE TO OFFICE ACTION**

TO THE COMMISSIONER FOR PATENTS,

SIR:

This response is being filed in response to the Office action mailed August 7, 2003, and to supplement the Amendment B and Response to Office action filed November 7, 2003.

**I. 35 U.S.C. 103(a) Rejection**

In addition to Applicants' argument that there is no motivation to combine the prior art cited by the Office (as detailed in Amendment B), Applicants are submitting with this response two journal articles, Crane et al.<sup>1</sup>, and Smith et al.<sup>2</sup>, that each disclose unexpected results for the claimed combination of celecoxib and gemcitabine.

---

<sup>1</sup>Crane et al., (2003) Am J Clin Oncol 26(4 suppl 2):S:81-S84.

<sup>2</sup>Smith et al., "Preliminary report of a phase II trial of gemcitabine combined with celecoxib for advanced pancreatic cancer" (Proc Am Soc Clin Oncol (2003) 22: page 374, Abstract No: 1502).

PHA 2012.1 (3167/4Z/US)  
PATENT

\* Briefly, Crane et al. test a number of different treatment regimes in a murine sarcoma model for pancreatic cancer.<sup>3</sup> In particular, Figure 1 on page S82 discloses the impact on tumor size after administration of celecoxib alone, vehicle alone, gemcitabine alone, radiation alone (i.e., 30 Gy), celecoxib in combination with gemcitabine, celecoxib in combination with radiation, gemcitabine in combination with radiation, and celecoxib in combination with radiation and gemcitabine. In view of their results, Crane et al. report that "celecoxib and gemcitabine on their own caused tumor growth delay for several days, **but when combined their effect was additive.**"<sup>4</sup>

\* In addition, it is reported in Smith et al. that "a combination of gemcitabine and celecoxib is active and well tolerated in patients with advanced pancreatic cancer."

The disclosure of Crane et al. and Smith et al. demonstrates the beneficial combination of celecoxib and gemcitabine, as compared to either compound administered alone, for use in treating or preventing neoplasia. Evidence of superior results not disclosed in the prior art is sufficient to establish non-obviousness.<sup>5</sup> In view of the superior results demonstrated by the applicants for the claimed combination, claim 1 is patentable over the cited art.

## II. Conclusion

\* In light of the foregoing, Applicants request entry of the attached publications along with the supplemental information disclosure enclosed with this response. Applicants also solicit an allowance of the claims. The Examiner is invited to contact the undersigned attorney should any issues remain unresolved.

---

<sup>3</sup>Crane et al., (2003) Am J Clin Oncol 26(4 suppl 2):S:81-S84.


<sup>4</sup>Crane et al., at page S82, column 2 (emphasis added); and Figure 1.

<sup>5</sup>See In re Chupp, 816 F.2d 643, 646, 2 USPQ2d 1437 (Fed. Cir. 1987) and cases cited therein.

PHA 2012.1 (3167/4Z/US)  
PATENT

The Commissioner is hereby authorized to charge any fees associated with this  
Response to Deposit Account 19-1345.

Respectfully submitted,



Kathryn J. Doty, Reg. No. 40,593  
SENNIGER, POWERS, LEAVITT & ROEDEL  
One Metropolitan Square, 16th Floor  
St. Louis, Missouri 63102  
(314) 231-5400

KJD/CDS/msc  
\*Attachment/Enclosures

By Facsimile No. (703) 872-9306 and  
Express Mail Label EV 324379158 US